SAVARA INC (SVRA)
Health Care · Clinical-stage biopharmaceutical company focused on rare/orphan respiratory diseases · NASDAQ
Clinical-stage biopharmaceutical company developing treatments for rare and orphan respiratory diseases.
What SAVARA INC does
Savara Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of medicines to treat rare and orphan respiratory diseases. The company is advancing product candidates through clinical trials with the aim of addressing unmet medical needs in respiratory conditions. Savara operates as an early-stage pharmaceutical development company with research and development as its primary operational focus, supported by general and administrative functions to manage regulatory, clinical, and corporate activities.
Themes: ["Rare respiratory diseases","Orphan drugs","Clinical development","Biopharmaceutical development","Clinical trial failure or inconclusive data results for product candidates could delay or prevent regulatory approvals","Substantial operating expenses and negative cash flows with limited cash runway; company is unprofitable and dependent on continued funding","Regulatory approval uncertainty; inability to obtain or maintain necessary regulatory approvals could prevent commercialization of product candidates","Genentech (rare respiratory disease developers)","Boehringer Ingelheim (pulmonary fibrosis focus)","Roche (orphan and rare disease portfolio)"]
Fundamentals
- Price$6.29 as of 2026-07-09 close
- Market cap$1.3B as of 2026-07-10
- 1-year return+165.4% as of 2026-07-09 close
- Net margin-4253.9% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE-87.2% as of 2026-07-10
- Debt / equity0.17 as of 2026-07-10
- Beta0.24 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.